Loading clinical trials...

Biobank For MS And Other Demyelinating Diseases | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Biobank For MS And Other Demyelinating Diseases

Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases

NCT00445367•Accelerated Cure Project for Multiple Sclerosis

Summary

To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
•willing to provide up to 110 ml (50 ml for \< 18 years old) of blood via venipuncture
•experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON

Exclusion Criteria

•history of blood borne pathogens
•allogeneic bone marrow transplant
•clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
•weight less than 37 pounds

Locations (10)

Barrow Neurological Institute

Phoenix, Arizona, United States

Stanford University

Stanford, California, United States

The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver

Aurora, Colorado, United States

Shepherd Center

Atlanta, Georgia, United States

Johns Hopkins

Baltimore, Maryland, United States

Beth Israel Deaconess

Boston, Massachusetts, United States

University of Massachusetts Medical School

Worcester, Massachusetts, United States

Multiple Sclerosis Research Center of New York

New York, New York, United States

The Ohio State University

Columbus, Ohio, United States

University of Texas Southwestern Medical Center at Dallas

Dallas, Texas, United States

Key Dates

Start Date

May 1, 2006

Primary Completion Date

October 1, 2030

Completion Date

October 1, 2036

Last Updated

October 2, 2025

Enrollment

3,226

ACTUAL participants

Conditions

Multiple SclerosisTransverse MyelitisNeuromyelitis OpticaAcute Disseminated EncephalomyelitisOptic Neuritis

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Biobank For MS And Other Demyelinating Diseases

Inclusion Criteria

Exclusion Criteria

Intermittent Hypoxia in Persons With Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis